June 6, 2012
Daiichi Sankyo and ArQule Inc. of the US have announced the results of the PII clinical trial for the investigational selective MET inhibitor tivantinib as second-line treatment in hepatocellular carcinoma (HCC). The HCC patients with MET-high tumors who received tivantinib...read more